These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 23287571)

  • 21. Mechanisms of disease: the role of heat-shock protein 90 in genitourinary malignancy.
    Lattouf JB; Srinivasan R; Pinto PA; Linehan WM; Neckers L
    Nat Clin Pract Urol; 2006 Nov; 3(11):590-601. PubMed ID: 17088927
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Heat shock protein 90: a unique chemotherapeutic target.
    Cullinan SB; Whitesell L
    Semin Oncol; 2006 Aug; 33(4):457-65. PubMed ID: 16890800
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Inhibition of cancer invasion and metastasis by targeting the molecular chaperone heat-shock protein 90.
    Koga F; Kihara K; Neckers L
    Anticancer Res; 2009 Mar; 29(3):797-807. PubMed ID: 19414312
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Identification of a new series of potent diphenol HSP90 inhibitors by fragment merging and structure-based optimization.
    Ren J; Li J; Wang Y; Chen W; Shen A; Liu H; Chen D; Cao D; Li Y; Zhang N; Xu Y; Geng M; He J; Xiong B; Shen J
    Bioorg Med Chem Lett; 2014 Jun; 24(11):2525-9. PubMed ID: 24751441
    [TBL] [Abstract][Full Text] [Related]  

  • 25. HSP90: a rising star on the horizon of anticancer targets.
    Dai C; Whitesell L
    Future Oncol; 2005 Aug; 1(4):529-40. PubMed ID: 16556029
    [TBL] [Abstract][Full Text] [Related]  

  • 26. 17-Allylamino-17-demethoxygeldanamycin induces the degradation of androgen receptor and HER-2/neu and inhibits the growth of prostate cancer xenografts.
    Solit DB; Zheng FF; Drobnjak M; Münster PN; Higgins B; Verbel D; Heller G; Tong W; Cordon-Cardo C; Agus DB; Scher HI; Rosen N
    Clin Cancer Res; 2002 May; 8(5):986-93. PubMed ID: 12006510
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Drugging the cancer chaperone HSP90: combinatorial therapeutic exploitation of oncogene addiction and tumor stress.
    Workman P; Burrows F; Neckers L; Rosen N
    Ann N Y Acad Sci; 2007 Oct; 1113():202-16. PubMed ID: 17513464
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Inhibition of Hsp90: a new strategy for inhibiting protein kinases.
    Sreedhar AS; Soti C; Csermely P
    Biochim Biophys Acta; 2004 Mar; 1697(1-2):233-42. PubMed ID: 15023364
    [TBL] [Abstract][Full Text] [Related]  

  • 29. HSP90 inhibitors: current development and potential in cancer therapy.
    Sidera K; Patsavoudi E
    Recent Pat Anticancer Drug Discov; 2014 Jan; 9(1):1-20. PubMed ID: 23312026
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Targeting heat shock response to sensitize cancer cells to proteasome and Hsp90 inhibitors.
    Zaarur N; Gabai VL; Porco JA; Calderwood S; Sherman MY
    Cancer Res; 2006 Feb; 66(3):1783-91. PubMed ID: 16452239
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Ganetespib and HSP90: translating preclinical hypotheses into clinical promise.
    Proia DA; Bates RC
    Cancer Res; 2014 Mar; 74(5):1294-300. PubMed ID: 24556722
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Hsp90: a novel target for the disruption of multiple signaling cascades.
    Bishop SC; Burlison JA; Blagg BS
    Curr Cancer Drug Targets; 2007 Jun; 7(4):369-88. PubMed ID: 17979631
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Advances in the role of heat shock protein 90 in prostate cancer.
    Fu Z; Jia B
    Andrologia; 2022 May; 54(4):e14376. PubMed ID: 35075667
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Combination therapies with HSP90 inhibitors against colorectal cancer.
    Kryeziu K; Bruun J; Guren TK; Sveen A; Lothe RA
    Biochim Biophys Acta Rev Cancer; 2019 Apr; 1871(2):240-247. PubMed ID: 30708039
    [TBL] [Abstract][Full Text] [Related]  

  • 35. SU086, an inhibitor of HSP90, impairs glycolysis and represents a treatment strategy for advanced prostate cancer.
    Rice MA; Kumar V; Tailor D; Garcia-Marques FJ; Hsu EC; Liu S; Bermudez A; Kanchustambham V; Shankar V; Inde Z; Alabi BR; Muruganantham A; Shen M; Pandrala M; Nolley R; Aslan M; Ghoochani A; Agarwal A; Buckup M; Kumar M; Going CC; Peehl DM; Dixon SJ; Zare RN; Brooks JD; Pitteri SJ; Malhotra SV; Stoyanova T
    Cell Rep Med; 2022 Feb; 3(2):100502. PubMed ID: 35243415
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Heat shock protein 90 inhibitors as broad spectrum anti-infectives.
    Rochani AK; Singh M; Tatu U
    Curr Pharm Des; 2013; 19(3):377-86. PubMed ID: 22920905
    [TBL] [Abstract][Full Text] [Related]  

  • 37. HSP90-Specific nIR Probe Identifies Aggressive Prostate Cancers: Translation from Preclinical Models to a Human Phase I Study.
    Osada T; Crosby EJ; Kaneko K; Snyder JC; Ginzel JD; Acharya CR; Yang XY; Polascik TJ; Spasojevic I; Nelson RC; Hobeika A; Hartman ZC; Neckers LM; Rogatko A; Hughes PF; Huang J; Morse MA; Haystead T; Lyerly HK
    Mol Cancer Ther; 2022 Jan; 21(1):217-226. PubMed ID: 34675120
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Starving lethal prostate cancer by targeting heat shock proteins and glycolytic enzymes.
    Plymate SR; Sprenger C; Haffner MC
    Cell Rep Med; 2022 Feb; 3(2):100493. PubMed ID: 35243412
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Mitochondrial Hsp90 chaperones as novel molecular targets in prostate cancer.
    Altieri DC
    Future Oncol; 2010 Apr; 6(4):487-9. PubMed ID: 20373861
    [No Abstract]   [Full Text] [Related]  

  • 40. Advances in the discovery and development of heat-shock protein 90 inhibitors for cancer treatment.
    Patel HJ; Modi S; Chiosis G; Taldone T
    Expert Opin Drug Discov; 2011 May; 6(5):559-587. PubMed ID: 22400044
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.